PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Company ReportsXeris Pharmaceuticals
Xeris Pharmaceuticals(XERS)
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
*Currency in USD
Loading
Company Revenue
Quarterly
Quarterly
Annual
Annual
Projections
*Quarterly sales USD (in millions)
Plot placeholder
Mock data
Subscribe for the real data
Revenue by Drug
Loading
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
KeveyisDichlorphenamide1982-01-01
Glaucoma
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Glucagon
healthy volunteers/patients
,
common cold
,
liver failure
,
hepatic insufficiency
,
chronic kidney failure
,
renal insufficiency
,
hyperglycemia
,
chronic renal insufficiency
,
binge-eating disorder
,
type 1 diabetes mellitus
,
hypoglycemia
,
glucose metabolism disorders
,
endocrine system diseases
,
weight loss
,
non-alcoholic fatty liver disease
,
fatty liver
,
left ventricular dysfunction
,
heart failure
,
nutrition disorders
,
obstructive sleep apnea
,
sleep apnea syndromes
,
apnea
,
prediabetic state
,
disease
,
motor activity
,
weight gain
,
ulcerative colitis
,
crohn disease
,
type 2 diabetes mellitus
,
obesity
,
diabetes mellitus
,
overweight
,
metabolic diseases
,
metabolic syndrome
,
body weight
,
coronary artery disease
,
psoriatic arthritis
,
psoriasis
,
myocardial ischemia
,
atherosclerosis
,
knee osteoarthritis
,
osteoarthritis
,
fasting
,
headache
,
pseudotumor cerebri
,
carcinoma
,
thyroid neoplasms
,
neuroendocrine carcinoma
,
papillary thyroid cancer
,
thyroid diseases
,
diabetic nephropathies
,
inflammation
Bevifimod
intervertebral disc degeneration
Insulin
healthy volunteers/patients
,
overweight
,
glucose metabolism disorders
,
endocrine system diseases
,
heart failure
,
hypoglycemia
,
gestational diabetes
,
non-small-cell lung carcinoma
,
lung neoplasms
,
type 1 diabetes mellitus
,
vascular diseases
,
type 2 diabetes mellitus
,
diabetes mellitus
,
insulin resistance
,
prediabetic state
,
hepatitis c
,
hepatitis
,
hepatitis a
,
chronic hepatitis c
,
obesity
,
hyperglycemia
,
hypertension
,
metabolic diseases
,
glucose intolerance
,
cardiovascular diseases
,
hiv
,
hospitalization
,
hypercholesterolemia
,
hepacivirus
,
cerebrovascular disorders
,
coronary artery disease
,
peripheral arterial disease
Viaject
healthy volunteers/patients
,
overweight
,
glucose metabolism disorders
,
endocrine system diseases
,
heart failure
,
hypoglycemia
,
gestational diabetes
,
non-small-cell lung carcinoma
,
lung neoplasms
,
type 1 diabetes mellitus
,
vascular diseases
,
type 2 diabetes mellitus
,
diabetes mellitus
,
insulin resistance
,
prediabetic state
,
hepatitis c
,
hepatitis
,
hepatitis a
,
chronic hepatitis c
,
obesity
,
hyperglycemia
,
hypertension
,
metabolic diseases
,
glucose intolerance
,
cardiovascular diseases
,
hiv
,
hospitalization
,
hypercholesterolemia
,
hepacivirus
,
cerebrovascular disorders
,
coronary artery disease
,
peripheral arterial disease
Pram9
type 1 diabetes mellitus
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use